<DOC>
	<DOCNO>NCT02977689</DOCNO>
	<brief_summary>The purpose study find drug IDH305 safe effective subject IDH1 mutant grade II III glioma progress observation radiation therapy .</brief_summary>
	<brief_title>Trial IDH305 IDH1 Mutant Grade II III Glioma</brief_title>
	<detailed_description>IDH305 orally available , brain-penetrant , mutant-selective allosteric IDH1 inhibitor block mutant IDH1-dependent production 2-HG .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Willing able provide write informed consent prior study related procedure comply study requirement . 2 . Subject must ≥18 year age . 3 . Patients must write documentation IDH1 mutation R132 locus immunohistochemistry DNA sequence tumor . 4 . Histopathological diagnosis glioma WHO grade II III initial diagnosis . Documentation diagnosis pathology report sufficient eligibility . 5 . First line management observation alone external beam radiation surgery . Notes record treat oncologist radiation oncologist require documentation treatment history . 6 . Patients must unequivocal progression brain MRI observation external beam radiation . If patient initially diagnose nonenhancing tumor tumor develop new contrastenhancement progression , exclude except follow exception : 1 . Patients tumor contrastenhancing initial diagnosis grade II III glioma allow tumor contrastenhancing progression well . 2 . If patient grade II III glioma tumor develop new contrastenhancement progression , enhance portion progressive tumor must biopsy proven WHO grade II III progression . 7 . Measurable tumor least 1 cm x 1 cm diameter MRI . The measurable tumor may contrastenhancing nonenhancing . 8 . Interval least 12 week completion prior radiotherapy registration . If patient pass interval least 12 week , may still eligible meet one follow criterion : 1 . New area tumor outside original radiotherapy field determine investigator , 2 . Histologic confirmation tumor ( opposed pseudoprogression radiation necrosis ) biopsy resection 9 . Collection archival tumor block minimum 1 cm2 surface area viable tumor least 20 unstained 5 micron slide recent surgery . 10 . Karnofsky performance status ( KPS ) ≥60 . 11 . An interval least 2 week ( start study agent ) prior surgical resection glioma , one week stereotactic biopsy glioma . 12 . Adequate hematologic , hepatic , renal function define absolute neutrophil count ≥1.0 x 109/L , hemoglobin ≥8 g/dL , platelet count ≥ 75 x 109/L ( may transfuse ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤3 x upper limit normal ( ULN ) , total bilirubin &gt; 1 x ULN , serum creatinine &gt; 1.5 x ULN 1 . Glioblastoma ( WHO grade IV ) histopathology tumor sample 2 . Leptomeningeal gliomatosis 3 . Unable tolerate contrastenhanced brain MRI MRI contraindicate 4 . Two week since major surgery treatment ( mediastinoscopy , insertion central venous access device insertion feed tube consider major surgery ) prior registration , exception stereotactic biopsy glioma , case interval 1 week registration allow . 5 . Patients currently receive treatment prohibit medication herbal remedy discontinue least one week prior start treatment . 1 . Narrow therapeutic index substrate CYP3A , CYP2C9 , CYP2C19 , CYP2C8 2 . Medications , herbs supplement strong inhibitor strong inducer CYP3A 3 . Other herbal preparation supplement 4 . Inhibitors UGT1A1 6 . Prior exposure therapy target IDH1 , include target inhibitor IDH1 antiIDH1 vaccine . 7 . Prior treatment cytotoxic chemotherapy , include limited temozolomide , lomustine , Nimustine Hydrochloride ( ACNU ) , bi ( chloroethyl ) nitrosourea ( BCNU ) , procarbazine , vincristine , carboplatin , irinotecan , Gliadel wafer , cyclophosphamide , etoposide , etc . Chemotherapy associate hypermutation phenotype recurrence therefore patient prior treatment agent exclude . 8 . Rapidly progress neurological symptom relate underlying disease require increase dos corticosteroid . Steroid use management glioma allow dose must stable least 1 week precede baseline MRI/CT . If corticosteroid dose increase date imaging initiation study treatment , new baseline MRI require . 9 . Malignant disease , treat study . Exceptions exclusion include follow : malignancy treat curatively recur within prior 2 year time registration ; completely resect basal cell squamous cell skin cancer ; malignancy consider indolent never require therapy ; completely resect carcinoma situ type . 10 . Patients correct QT use Fridericia correction ( QTcF ) &gt; 470 msec , clinically significant , uncontrolled heart disease , include acute myocardial infarction unstable angina &lt; 3 month prior first dose IDH305 . 11 . Any medical condition would , investigator 's judgment , prevent patient 's participation clinical study due safety concern compliance clinical study procedure presence clinically significant cardiac , respiratory , gastrointestinal , renal , hepatic , infectious , psychiatric neurological disease . 12 . Patients Gilbert 's syndrome heritable disease bile processing . 13 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 14 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , unless use highly effective method contraception dose 30 day use investigational medication . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle patient ) . Periodic abstinence ( e.g. , calendar , ovulation , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) , total hysterectomy , tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . The vasectomized male partner sole partner patient Combination two follow ( a+b , a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal , example hormone vaginal ring transdermal hormone contraception . In case use oral contraception woman stable pill minimum 3 month take study treatment . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository 15 . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) , total hysterectomy tubal ligation least six week prior screen . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 16 . Sexually active male must use condom intercourse take drug 30 day stop treatment father child period . A condom require use also vasectomize men well intercourse male partner order prevent delivery drug via semen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Isocitrate dehydrogenase ( IDH )</keyword>
	<keyword>R-2-Hydroxyglutarate ( 2-HG )</keyword>
	<keyword>Gene encode UDP-glucuronosyltransferase ( UGT1A1 )</keyword>
	<keyword>Glioblastoma ( GBM )</keyword>
	<keyword>IDH305</keyword>
	<keyword>IDHR132 mutation</keyword>
	<keyword>Astrocytoma</keyword>
	<keyword>Oligodendroglioma</keyword>
	<keyword>Oligoastrocytoma</keyword>
	<keyword>IDH1 R132H</keyword>
	<keyword>IDH1</keyword>
</DOC>